Benign Prostatic Hyperplasia (BPH) Drugs Market Report

Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 21, 2020
  • PAGES：150
  • REPORT CODE：GMM573633
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Benign Prostatic Hyperplasia (BPH) Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 1.6% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Segmentations:

    By Player:

    • Spectrum Pharmaceuticals

    • Sanofi

    • Valeant Pharmaceuticals

    • Bayer HealthCare

    • Madrigal Pharmaceuticals

    • Astellas Pharma

    • Advaxis

    • Merck

    • Teva

    • GlaxoSmithKline

    • Novartis

    • BHR Pharma

    • ANI Pharmaceuticals

    • ADC Therapeutics

    • Eli Lilly

    • Bristol-Myers Squibb

    • Endo Pharmaceuticals

    • Takeda Pharmaceuticals

    • Foresee Pharmaceuticals

    By Type:

    • Alpha-blocker

    • Phosphodiesterase Type-5 Inhibitors

    • 5-alpha-Reductase Inhibitors

    By End-User:

    • Hospitals

    • Clinics

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Benign Prostatic Hyperplasia (BPH) Drugs Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-blocker from 2014 to 2026

    • 1.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors from 2014 to 2026

    • 1.3.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-alpha-Reductase Inhibitors from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

    • 1.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • 1.4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Benign Prostatic Hyperplasia (BPH) Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Benign Prostatic Hyperplasia (BPH) Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Alpha-blocker

      • 3.4.2 Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors

      • 3.4.3 Market Size and Growth Rate of 5-alpha-Reductase Inhibitors

    4 Segmentation of Benign Prostatic Hyperplasia (BPH) Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Benign Prostatic Hyperplasia (BPH) Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Hospitals for Construction

      • 4.4.2 Market Size and Growth Rate of Clinics for Construction

      • 4.4.3 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Production Analysis by Top Regions

    • 5.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Analysis by Top Regions

    • 5.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.3 France Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    6 Product Circulation of Benign Prostatic Hyperplasia (BPH) Drugs Market among Top Countries

    • 6.1 Top 5 Export Countries in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 7.1 Germany Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 7.2 Germany Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    8. UK Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 8.1 UK Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 8.2 UK Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    9. France Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 9.1 France Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 9.2 France Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    10. Italy Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 10.1 Italy Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 10.2 Italy Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    11. Spain Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 11.1 Spain Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 11.2 Spain Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    12. Poland Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 12.1 Poland Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 12.2 Poland Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    13. Russia Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 13.1 Russia Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 13.2 Russia Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    14. Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 14.1 Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 14.2 Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    15. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 15.1 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 15.2 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Top Countries

      • 16.3.1 Denmark Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

      • 16.3.2 Finland Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

      • 16.3.3 Norway Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

      • 16.3.4 Sweden Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

      • 16.3.6 Iceland Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Top Countries

      • 17.3.1 Belgium Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

      • 17.3.2 Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

      • 17.3.3 Luxembourg Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Landscape Analysis by Top Countries

      • 18.3.1 Estonia Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

      • 18.3.2 Latvia Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

      • 18.3.3 Lithuania Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Spectrum Pharmaceuticals

      • 19.1.1 Spectrum Pharmaceuticals Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Sanofi

      • 19.2.1 Sanofi Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Valeant Pharmaceuticals

      • 19.3.1 Valeant Pharmaceuticals Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Bayer HealthCare

      • 19.4.1 Bayer HealthCare Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Madrigal Pharmaceuticals

      • 19.5.1 Madrigal Pharmaceuticals Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Astellas Pharma

      • 19.6.1 Astellas Pharma Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Advaxis

      • 19.7.1 Advaxis Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Merck

      • 19.8.1 Merck Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Teva

      • 19.9.1 Teva Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 GlaxoSmithKline

      • 19.10.1 GlaxoSmithKline Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Novartis

      • 19.11.1 Novartis Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 BHR Pharma

      • 19.12.1 BHR Pharma Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 ANI Pharmaceuticals

      • 19.13.1 ANI Pharmaceuticals Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 ADC Therapeutics

      • 19.14.1 ADC Therapeutics Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Eli Lilly

      • 19.15.1 Eli Lilly Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Bristol-Myers Squibb

      • 19.16.1 Bristol-Myers Squibb Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Endo Pharmaceuticals

      • 19.17.1 Endo Pharmaceuticals Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Takeda Pharmaceuticals

      • 19.18.1 Takeda Pharmaceuticals Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Foresee Pharmaceuticals

      • 19.19.1 Foresee Pharmaceuticals Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    The List of Tables and Figures (Totals 115 Figures and 173 Tables)

    • Figure Product Picture

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-blocker Market, 2015 - 2026 (USD Million)

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors Market, 2015 - 2026 (USD Million)

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-alpha-Reductase Inhibitors Market, 2015 - 2026 (USD Million)

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure France Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Benign Prostatic Hyperplasia (BPH) Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Benign Prostatic Hyperplasia (BPH) Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Benign Prostatic Hyperplasia (BPH) Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of Benign Prostatic Hyperplasia (BPH) Drugs by Different Types from 2014 to 2026

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-blocker Market, 2015 - 2026 (USD Million)

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors Market, 2015 - 2026 (USD Million)

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-alpha-Reductase Inhibitors Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Benign Prostatic Hyperplasia (BPH) Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of Benign Prostatic Hyperplasia (BPH) Drugs by Different End-Users from 2014 to 2026

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Production by Major Regions

    • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Major Regions

    • Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Production Share by Major Countries and Regions in 2014

    • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Major Regions

    • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Regions

    • Table Germany Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table UK Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table France Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Italy Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Spain Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Poland Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Russia Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Turkey Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Benign Prostatic Hyperplasia (BPH) Drugs Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table France Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table France Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table France Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table France Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Poland Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Poland Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Poland Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Poland Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Switzerland Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Benign Prostatic Hyperplasia (BPH) Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Benign Prostatic Hyperplasia (BPH) Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Spectrum Pharmaceuticals Profiles

    • Table Spectrum Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Spectrum Pharmaceuticals Product benchmarking

    • Table Spectrum Pharmaceuticals Strategic initiatives

    • Table Spectrum Pharmaceuticals SWOT analysis

    • Table Sanofi Profiles

    • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

    • Table Sanofi Product benchmarking

    • Table Sanofi Strategic initiatives

    • Table Sanofi SWOT analysis

    • Table Valeant Pharmaceuticals Profiles

    • Table Valeant Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Valeant Pharmaceuticals Product benchmarking

    • Table Valeant Pharmaceuticals Strategic initiatives

    • Table Valeant Pharmaceuticals SWOT analysis

    • Table Bayer HealthCare Profiles

    • Table Bayer HealthCare Production, Value, Price, Gross Margin 2014-2019

    • Table Bayer HealthCare Product benchmarking

    • Table Bayer HealthCare Strategic initiatives

    • Table Bayer HealthCare SWOT analysis

    • Table Madrigal Pharmaceuticals Profiles

    • Table Madrigal Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Madrigal Pharmaceuticals Product benchmarking

    • Table Madrigal Pharmaceuticals Strategic initiatives

    • Table Madrigal Pharmaceuticals SWOT analysis

    • Table Astellas Pharma Profiles

    • Table Astellas Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Astellas Pharma Product benchmarking

    • Table Astellas Pharma Strategic initiatives

    • Table Astellas Pharma SWOT analysis

    • Table Advaxis Profiles

    • Table Advaxis Production, Value, Price, Gross Margin 2014-2019

    • Table Advaxis Product benchmarking

    • Table Advaxis Strategic initiatives

    • Table Advaxis SWOT analysis

    • Table Merck Profiles

    • Table Merck Production, Value, Price, Gross Margin 2014-2019

    • Table Merck Product benchmarking

    • Table Merck Strategic initiatives

    • Table Merck SWOT analysis

    • Table Teva Profiles

    • Table Teva Production, Value, Price, Gross Margin 2014-2019

    • Table Teva Product benchmarking

    • Table Teva Strategic initiatives

    • Table Teva SWOT analysis

    • Table GlaxoSmithKline Profiles

    • Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019

    • Table GlaxoSmithKline Product benchmarking

    • Table GlaxoSmithKline Strategic initiatives

    • Table GlaxoSmithKline SWOT analysis

    • Table Novartis Profiles

    • Table Novartis Production, Value, Price, Gross Margin 2014-2019

    • Table Novartis Product benchmarking

    • Table Novartis Strategic initiatives

    • Table Novartis SWOT analysis

    • Table BHR Pharma Profiles

    • Table BHR Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table BHR Pharma Product benchmarking

    • Table BHR Pharma Strategic initiatives

    • Table BHR Pharma SWOT analysis

    • Table ANI Pharmaceuticals Profiles

    • Table ANI Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table ANI Pharmaceuticals Product benchmarking

    • Table ANI Pharmaceuticals Strategic initiatives

    • Table ANI Pharmaceuticals SWOT analysis

    • Table ADC Therapeutics Profiles

    • Table ADC Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table ADC Therapeutics Product benchmarking

    • Table ADC Therapeutics Strategic initiatives

    • Table ADC Therapeutics SWOT analysis

    • Table Eli Lilly Profiles

    • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

    • Table Eli Lilly Product benchmarking

    • Table Eli Lilly Strategic initiatives

    • Table Eli Lilly SWOT analysis

    • Table Bristol-Myers Squibb Profiles

    • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

    • Table Bristol-Myers Squibb Product benchmarking

    • Table Bristol-Myers Squibb Strategic initiatives

    • Table Bristol-Myers Squibb SWOT analysis

    • Table Endo Pharmaceuticals Profiles

    • Table Endo Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Endo Pharmaceuticals Product benchmarking

    • Table Endo Pharmaceuticals Strategic initiatives

    • Table Endo Pharmaceuticals SWOT analysis

    • Table Takeda Pharmaceuticals Profiles

    • Table Takeda Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Takeda Pharmaceuticals Product benchmarking

    • Table Takeda Pharmaceuticals Strategic initiatives

    • Table Takeda Pharmaceuticals SWOT analysis

    • Table Foresee Pharmaceuticals Profiles

    • Table Foresee Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Foresee Pharmaceuticals Product benchmarking

    • Table Foresee Pharmaceuticals Strategic initiatives

    • Table Foresee Pharmaceuticals SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US